CIP
KRYS icon

Chartwell Investment Partners’s Krystal Biotech KRYS Stock Holding History

Chartwell Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,018
Closed -$301K – 429
2020
Q4 		$301K Sell
5,018
-14,912
-75% -$745K 0.01% 418
2020
Q3 		$858K Hold
19,930
– – 0.03% 363
2020
Q2 		$826K Sell
19,930
-5,861
-23% -$282K 0.03% 348
2020
Q1 		$1.11M Buy
25,791
+2,931
+13% +$153K 0.05% 310
2019
Q4 		$1.27M Sell
22,860
-22,422
-50% -$1.1M 0.04% 339
2019
Q3 		$1.57M Buy
+45,282
New +$2.02M 0.05% 335

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chartwell Investment Partners's KRYS Position: Q1 2021 in Review

Chartwell Investment Partners sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 5,018 shares — an estimated $301K sold.

Chartwell Investment Partners first reported a position in KRYS in Q3 2019 and held it in 6 quarters. The position peaked at $1.57M in Q3 2019. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

  • Chartwell Investment Partners reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
  • Chartwell Investment Partners sold 5,018 Krystal Biotech shares in Q1 2021, an estimated $301K.
  • Chartwell Investment Partners first reported a position in Krystal Biotech in Q3 2019 and held it in 6 quarters.
  • Chartwell Investment Partners's Krystal Biotech position peaked at $1.57M in Q3 2019.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on Chartwell Investment Partners's 13F filing for Q1 2021, filed 3 May 2021.